Quick Takeaways
- Thomas J. Schall has 2 issuer positions tracked on this page.
- Estimated disclosed ownership value: $347,913.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Thomas J. Schall
- Location
- Mountain View, CA
- Summary
- The estimated net worth of Thomas J. Schall is at least $347,913 dollars as of 20 Jan 2026. Thomas J. Schall is the Director of Immuneering Corp and owns shares of Immuneering Corp (IMRX) stock worth about $347.9K.
- Signature
- /s/ Michael D. Bookman, Attorney-in-Fact for Thomas J. Schall
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Thomas J. Schall and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
What Changed
- Largest disclosed position: Immuneering Corp ($347,913).
- Past-year value change for that position: +$225,107.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Thomas J. Schall
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| IMRX | Immuneering Corp | Director | $347,913 | +$225,107 | +183% | 15 Jan 2026 |
| CCXI | ChemoCentryx, Inc. | President and CEO, Director | 20 Oct 2022 |
Insider Transactions Reported by Thomas J. Schall:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.